Analysts’ consensus target price for MYL stock
According to the analysts surveyed by Reuters, the consensus target price for Mylan (MYL) stock is $46.61. This target price implies an ~24.0% return based on MYL’s September 25 closing price of $37.62.
On September 26, analysts’ average target prices for Mylan’s peers Teva Pharmaceutical (TEVA), Pfizer (PFE), and Amgen (AMGN) are $21.00, $42.40, and $204.10, respectively, implying potential returns of -9.8%, -3.2%, and -1.2%.
Recent ratings and target price updates
On September 17, Leerink Partners raised its target price on Mylan (MYL) stock from $47.00 to $48.00. On August 16, Mizuho Securities cut its target price on the stock from $54.00 to $50.00. On that day, Teva Pharmaceutical Industries received FDA approval for its generic version of EpiPen, Mylan’s blockbuster allergy product.
On August 24, Evercore ISI upgraded its recommendation on Mylan stock from “in line” to “outperform.” On August 13, RBC Capital Markets also raised its recommendation on Mylan stock from “sector perform” to “outperform” while raising its target price on the stock from $42.00 to $51.00. On April 12, Mylan stock was upgraded by Leerink Partners from a rating of “market perform” to “outperform.”
In the next article, we’ll discuss Mylan’s recent stock price performance.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!